Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a real-life study.
Davide MassanoElisa CarraroLara MussolinSalvatore BuffardiVeronica BaratDaniele ZamaPaola MuggeoFrancesca VendeminiAntonella SauMaria Luisa MoletiFederico VerzegnassiSalvatore D'AmicoTommaso CasiniAlberto GaraventaElisabetta SchiavelloMonica CelliniLuciana VintiPiero FarruggiaKatia PerruccioSimone CesaroRaffaela De SantisMaddalena MarinoniIrene D'AlbaRosa Maria MuraRoberta BurnelliMaurizio MascarinMarta PillonPublished in: Pediatric blood & cancer (2022)
In conclusion, our study confirms that BV was a safe and effective drug, able to induce complete remission, either as monotherapy or in association with standard therapy.
Keyphrases
- hodgkin lymphoma
- diffuse large b cell lymphoma
- emergency department
- intensive care unit
- acute lymphoblastic leukemia
- stem cells
- randomized controlled trial
- clinical trial
- mesenchymal stem cells
- combination therapy
- lps induced
- bone marrow
- inflammatory response
- disease activity
- study protocol
- replacement therapy
- smoking cessation